ImmunityBio Resubmits ANKTIVA Application for Treating Non-Muscle Invasive Bladder Cancer

ImmunityBio Resubmits Application for ANKTIVA in NMIBC Treatment

ImmunityBio, a commercial-stage immunotherapy company located in Culver City, California, has taken significant steps forward by resubmitting its supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) to the U.S. Food and Drug Administration (FDA). This application specifically targets the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) characterized by papillary tumors. Following extensive discussions with the FDA, which commenced in January 2026, the agency requested additional data to facilitate the review process. After providing follow-up data in February and receiving further feedback in March, ImmunityBio emphasizes its commitment to addressing the pressing medical needs of the approximate 60,000 patients diagnosed with NMIBC annually in the U.S.

In highlighting the urgency of this resubmission, Dr. Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio, stresses the importance of long-term safety and efficacy data for ANKTIVA combined with Bacillus Calmette-Guérin (BCG) treatment. This combination has been corroborated by publications in reputable medical journals, including The Journal of Urology. Dr. Soon-Shiong specifically points to interleukin-15 (IL-15) as a compelling therapeutic agent known to enhance survival rates among patients suffering from papillary disease. By advancing the discussion on IL-15’s potential, ImmunityBio seeks to bolster its position in the competitive landscape of cancer therapies while addressing an unmet need for bladder preservation and improved disease-free survival rates in NMIBC patients.

ImmunityBio's previous approval in 2024 for the use of ANKTIVA in treating NMIBC with carcinoma in situ (CIS), either alone or alongside papillary tumors, sets a precedent for the drug's effectiveness. The recent resubmission aims to extend the therapeutic benefits to patients facing the specific challenges posed by papillary tumors. By reinforcing its existing knowledge base and addressing the unique needs of this patient population, ImmunityBio hopes to not only support positive health outcomes but also reinforce its role as a leader in the biopharmaceutical industry dedicated to innovative cancer treatments.

In addition to its regulatory efforts, ImmunityBio's strategic decisions and clinical trial outcomes serve as vital indicators of its future direction in a rapidly evolving biotechnology environment. As the company navigates the complexities associated with immunotherapy development, stakeholder engagement continues to be a crucial element for maintaining investor confidence and enhancing market positioning.

Overall, ImmunityBio is making strides towards addressing the challenges of NMIBC treatment, reflecting its commitment to advancing therapeutic options in the oncology space while further solidifying its emerging role within the biopharmaceutical sector.